Summary
Muvalaplin is a groundbreaking oral medication, developed by Eli Lilly and Company, aimed at inhibiting the formation of lipoprotein(a) (Lp(a)), a genetically inherited risk factor for heart disease. The medication works by interrupting the interaction between apolipoprotein(a) [apo(a)] and apolipoproteinB (apoB), thus reducing the production of Lp(a). This novel approach marks muvalaplin as a potential first-of-its-kind oral treatment for Lp(a) related heart disease risk.
Approximately 20% of the U.S. population, or around 63 million individuals, have high levels of Lp(a), which can double or triple their risk of heart attacks and other cardiovascular issues. Currently, there are no approved medications specifically designed to lower Lp(a), which makes the development of muvalaplin a significant advancement in the field of cardiovascular health. The promising results from a 12-week Phase 2 study, where muvalaplin reduced Lp(a) levels by up to 65% in participants, have spurred further research into this medication.
The side effects of muvalaplin have been reported to include headaches, back pain, fatigue, diarrhea, abdominal pain, and nausea, but the medication is generally well-tolerated with no significant adverse effects observed in the study. Despite these positive findings, further research is needed to confirm whether the lowering of Lp(a) levels through muvalaplin use will result in fewer heart attacks and strokes.
This research is particularly important given the high prevalence of elevated Lp(a) levels, a known risk factor for various cardiovascular diseases. The discontinuation of an earlier Eli Lilly drug targeting Lp(a) due to perceived inability to prevent heart attacks and strokes underscores the importance and challenge of this ongoing research. The future direction of this field hinges on large-scale, randomized, controlled trials that can effectively evaluate the impact of lowering Lp(a) on cardiovascular outcomes.
The Miracle Drug: Muvalaplin
Muvalaplin is an oral, once-daily treatment that inhibits the formation of lipoprotein(a) or Lp(a), a genetically inherited risk factor for heart disease. It achieves this through a novel mechanism that blocks the initial interaction between apolipoprotein(a) [apo(a)] and apolipoproteinB (apoB), thereby reducing the formation of Lp(a). Developed by Eli Lilly and Company, muvalaplin achieved positive results in a 12-week Phase 2 study.
It is important to note that about 20% of people, or approximately 63 million individuals in the U.S. have high levels of Lp(a). Elevated Lp(a) levels can double or even triple the risk of a heart attack and are associated with other cardiovascular issues. As such, muvalaplin presents a significant advancement in cardiovascular risk reduction.
The Phase 2 study found that muvalaplin led to a maximum placebo-adjusted Lp(a) reduction of 63% to 65%, bringing Lp(a) plasma levels to less than 50 mg/dL in 93% of the study participants. This, alongside its novel approach to disrupting Lp(a) formation, makes muvalaplin the first of its kind in oral Lp(a) treatments.
In terms of safety and tolerability, the most commonly reported side effects of muvalaplin included headache, back pain, fatigue, diarrhea, abdominal pain, and nausea. Nevertheless, the study did not associate muvalaplin with any tolerability concerns or clinically significant adverse effects.
Currently, although there are no approved drug treatments to lower Lp(a), Lilly is conducting a second Phase 3 trial to determine if lowering Lp(a) with muvalaplin indeed reduces heart attack risks. However, more research is required to determine if Lp(a) lowering will result in fewer heart attacks and strokes.
The Global Impact of Elevated Lp(a) Levels
Elevated Lp(a) levels are a common risk factor for cardiovascular diseases, affecting 20–30% of the global population with levels >30 mg/dL. In the United States, about 63 million individuals or roughly 20% of the population have high levels of Lp(a). The prevalence and impacts of elevated Lp(a) levels are well-documented through epidemiologic studies and meta-analyses, genome-wide association studies, and Mendelian randomization studies, which have confirmed the independent, genetic risk factor of Lp(a) for cardiovascular disease.
High Lp(a) levels have been linked to a higher risk of numerous cardiovascular diseases, including heart attack, stroke, irregular heart rhythms, heart valve disease, and limited lower-body circulation. These high levels can double or even triple the risk of heart attacks and are associated with other cardiovascular issues. The risk is further increased for individuals with FH or signs of coronary heart disease.
There are several conditions and treatments that have been identified as factors affecting Lp(a) levels. Inflammatory conditions, pregnancy, hypothyroidism, growth hormone therapy, and kidney disease can increase levels, while severe acute phase conditions, postmenopausal hormone replacement, hyperthyroidism, and liver disease can decrease them. It is thus recommended to monitor Lp(a) levels during steady states to ensure accurate assessment.
Recently, trials of new drug muvalaplin, an oral agent, showed promise in lowering Lp(a) levels with no significant adverse effects, thus potentially offering a new therapy for those with elevated Lp(a). However, the effectiveness of this and other drugs in reducing major adverse cardiovascular events (MACE) has yet to be fully established, highlighting the need for ongoing research and trials. The results of these studies might be of paramount importance in managing the risk of arteriosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis, which Lp(a) is an established independent casual risk factor for.
The Promise of Lp(a) Targeting Therapies
Lipoprotein(a), commonly known as Lp(a), is a genetically inherited risk factor for heart disease. The development of therapies targeting Lp(a) is gaining attention due to their promising results in clinical trials. These therapies can potentially benefit patients with high-risk cardiovascular conditions, such as those with prior ASCVD events or Lp(a) levels at around the 90th percentile.
Lp(a) Lowering Drugs
Current development of Lp(a) lowering drugs includes siRNA treatments like Zerlasiran and antisense oligonucleotides (ASO) such as TQJ230. These drugs work by interrupting the production of Lp(a) in the liver. Although there are existing therapies for reducing heart disease risk by lowering LDL cholesterol and other lipids, there are currently no approved treatments specifically targeting Lp(a). This emphasizes the potential of these investigational drugs.
### Clinical Trials
Currently, two major clinical trials are underway to investigate the efficacy of Lp(a) lowering drugs. These include the phase 3 HORIZON trial, which investigates the impact of Lp(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease. However, despite the promising results, the clinical relevance of reducing Lp(a) is yet to be determined. Future trials may need to focus on patients with elevated Lp(a) levels and consider patients’ clinical context.
Challenges and Limitations
While research on the drug muvalaplin has shown promise in lowering Lp(a) levels, there are several challenges and limitations that must be taken into account. Despite the degree of Lp(a)-lowering shown in patients who are likely to benefit most from its use, further studies are needed to determine whether this will translate into a decrease in cardiovascular events such as heart attacks and strokes.
At present, evidence is lacking to determine the clinical relevance of reducing Lp(a) levels. The need for large-scale, randomized, controlled trials to evaluate cardiovascular outcomes associated with lowering Lp(a) is evident. Given the development of multiple targeted Lp(a)-lowering therapies, it’s important to clarify the populations of patients who may benefit from these promising therapies. This includes individuals at highest risk, such as those with prior ASCVD events and high Lp(a) levels.
Lastly, there are substantial risks and uncertainties involved in the process of drug research, development, and commercialization. There is no guarantee that planned or ongoing studies will be completed as planned, or that muvalaplin will receive regulatory approval. These potential hurdles further underscore the challenges and limitations in the ongoing efforts to lower Lp(a) levels and reduce the associated cardiovascular risk.
Importance and Implications of Eli Lilly’s Breakthrough Drug
Eli Lilly, a prominent pharmaceutical company, announced it was discontinuing the development of a drug designed to combat cardiovascular diseases due to its suspected inability to prevent heart attacks and strokes. This decision was made public at the annual meeting of the American College of Cardiology and coincided with the publication of the Lilly research in the New England Journal of Medicine.
The drug was intended to inhibit the body’s production of Lp(a), a combination of lipids and a protein, which is an acknowledged cause of cardiovascular disease when present in high levels. Elevated levels of Lp(a) have been linked to a range of cardiovascular conditions, including heart attacks, strokes, irregular heart rhythms, and heart valve diseases. As per estimates, 20-30% of the global population has Lp(a) levels greater than 30 mg/dL, marking it as a highly prevalent cardiovascular risk factor.
However, despite the strong correlation between high Lp(a) levels and increased cardiovascular disease risk, there is a lack of concrete evidence to determine the clinical relevance of reducing Lp(a). Further, there are no existing specific therapies developed to lower Lp(a) levels. Therefore, the cessation of the development of Eli Lilly’s drug presents a significant setback in the field of cardiovascular disease research and treatment.
While Eli Lilly’s drug may not have met expectations, the focus on Lp(a) offers valuable insights into future directions of research in cardiovascular disease treatments. Future clinical trials may potentially focus on patients with high baseline Lp(a) levels, alongside optimal treatment for other cardiovascular risk factors, to yield meaningful reductions in Lp(a) levels. Furthermore, the context of these trials should also consider the baseline Lp(a) levels and the existing health condition of the participants.
The halt in the development of Eli Lilly’s drug underscores the need for large-scale, randomized, controlled trials to evaluate cardiovascular outcomes associated with lowering Lp(a). It also emphasizes the importance of considering potential confounding factors, such as differences in concurrent therapies, in future studies. Despite the setback, the research on Lp(a) continues to hold promise for the development of effective cardiovascular disease treatments in the future.
Future Directions
Eli Lilly’s groundbreaking research has revealed an experimental drug, lepodisiran, capable of significantly reducing the level of Lp(a) – a particle in the blood associated with increased risk of heart attacks and strokes – in individuals. The drug has demonstrated its potential to reduce Lp(a) levels by 94 percent with a single injection. Nevertheless, while these preliminary results are promising, it is still uncertain whether reducing Lp(a) levels will also diminish the risk of heart attacks and strokes. To clarify this relationship, larger clinical trials are presently being conducted.
In parallel with these studies, researchers are also examining muvalaplin, an orally administered small molecule that suppresses the formation of Lp(a) by obstructing the interaction between apo(a) and apo B100. This phase 1 study has demonstrated that muvalaplin can lower Lp(a) levels by up to 65% after 14 days of daily administration, with no significant tolerability concerns. Nevertheless, additional extensive and longer-term trials will be necessary to further assess muvalaplin’s safety, tolerability, and impact on Lp(a) levels and cardiovascular outcomes.
Moreover, the TQJ230 Horizon trial is currently underway to determine if lowering Lp(a) will provide a clinical benefit in patients with established cardiovascular disease. As the field progresses, identifying the populations that will benefit the most from reducing Lp(a) will be crucial.
Despite these challenges and uncertainties, the ongoing research and clinical trials conducted by Eli Lilly and other companies represent significant strides in addressing this critical cardiovascular risk factor, bringing hope for improved treatments and outcomes in the near future.
The content is provided by Avery Redwood, Lifelong Health Tips
